Cinnamon Cognition Randomized Trial: What the Evidence Says
Cinnamon Cognition Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are ran
Quick Answer
Cinnamon Cognition Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence aware guidance rather than medical advice.
Key Takeaways
- 01This page is generated only from sources stored in the Migaku evidence knowledge base.
- 02Current evidence mix: 1 randomized trial, 1 narrative review.
- 03Claims should be interpreted with the source type, study design, population, and publication date in mind.
- 04This article is educational and does not replace care from a qualified clinician.
Cinnamon Cognition Randomized Trial: What the Evidence Says
Quick Answer
Cinnamon Cognition Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.
Key Takeaways
- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 randomized trial, 1 narrative review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.
Evidence Map
| Source | Evidence type | Level | Date | Identifier |
|---|---|---|---|---|
| Study of Chemosensory Enhancement through Neuromodulation Training (SCENT): Design and methodology of a randomized clinical trial for COVID-related persistent smell dysfunction ☆ | randomized trial | 2 | 2026-02-01 | 10.1016/j.conctc.2025.101582 |
| Harnessing phytochemicals for engineering health solutions | narrative review | 3 | 2026-01-22 | 10.1186/s40246-025-00882-y |
What The Sources Report
- Symptoms of Long COVID include the onset of new psychiatric problems including increased anxiety and depression, cognitive impairment, often referred to as "brain fog", as well as sleep dysfunction and daytime fatigue. [Cash Nicole (2026); evidence level 2]
- Trigeminal nerve stimulation (TNS) is a novel, non-invasive, pain-free, method of neuromodulation currently being used to reduce symptoms associated with a wide range of neuropsychiatric conditions including disturbances in mood, sleep, and cognition. [Cash Nicole (2026); evidence level 2]
- A growing body of evidence supports the therapeutic potential of volatile terpenes such as limonene (from citrus) and pinene (from pine and sage), which have been specifically studied for their anti-inflammatory, antioxidant, and neuroprotective activities. [Kim Jenny Ji Hyun (2026); evidence level 3]
- However, despite its originally agnostic intent, exposome research has disproportionately focused on adverse exposures and disease risk. [Kim Jenny Ji Hyun (2026); evidence level 3]
How To Read This Evidence
Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.
Practical Interpretation
There is trial evidence in the current set, but population and intervention details still matter. For cinnamon cognition randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.
Limits Of This First Pass
This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.
References
- Cash Nicole (2026). Study of Chemosensory Enhancement through Neuromodulation Training (SCENT): Design and methodology of a randomized clinical trial for COVID-related persistent smell dysfunction ☆. DOI: 10.1016/j.conctc.2025.101582. PMCID: PMC12756551. PMID: 41488386. License: https://creativecommons.org/licenses/by-nc-nd/4.0/. https://pmc.ncbi.nlm.nih.gov/articles/PMC12756551/
- Kim Jenny Ji Hyun (2026). Harnessing phytochemicals for engineering health solutions. DOI: 10.1186/s40246-025-00882-y. PMCID: PMC12910803. PMID: 41572398. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12910803/
Safety Note
Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.
FAQ
Frequently Asked Questions
Medically reviewed
Last reviewed July 26, 2026 by Migaku Evidence Review
